K. Haworth

University of Birmingham Using a human challenge model of infection to measure vaccine efficacy

G. Dougan, M. Levine, S. Lockhart, 2016 .

Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults

A. Nicosia, P. Klenerman, A. Pollard, 2019, Journal of Infection.

Chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine is safe and expands humoral and cellular immunity in adults

A. Folgori, R. Cortese, A. Nicosia, 2015 .

A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial

J. Derrick, M. Shanyinde, M. Maiden, 2015, The Journal of infection.

Randomized Clinical Trial To Evaluate the Immunogenicity of Quadrivalent Meningococcal Conjugate and Polysaccharide Vaccines in Adults in the United Kingdom

G. Blanchard-Rohner, Ly-Mee Yu, A. Pollard, 2014, Clinical and Vaccine Immunology.

An Outpatient, Ambulant-Design, Controlled Human Infection Model Using Escalating Doses of Salmonella Typhi Challenge Delivered in Sodium Bicarbonate Solution

J. Farrar, G. Dougan, K. Holt, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Chimpanzee adenovirus– and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults

Andrew J. Pollard, A. Folgori, R. Cortese, 2015, Science Translational Medicine.

Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21a

G. Dougan, M. Levine, S. Lockhart, 2016, PLoS neglected tropical diseases.